HomeHealthFDA looking into reports of hair loss, suicidal thoughts in people using...

FDA looking into reports of hair loss, suicidal thoughts in people using popular drugs for diabetes and weight loss

Published on

spot_img


The U.S. Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications like Ozempic, Mounjaro and Wegovy.These drugs, known as GLP-1 receptor agonists, are approved to treat diabetes or weight loss. They include semaglutide, branded as Ozempic, Rybelsus and Wegovy; liragutide, branded as Saxenda and Victoza; and tirzepatide, branded as Mounjaro and Zepbound. They mimic GLP-1, a hormone made naturally in the body whose roles include slowing the passage of food through the stomach.The FDA is “evaluating the need for regulatory action” after its FDA Adverse Event Reporting System or FAERS received reports of alopecia, or hair loss; aspiration, or accidentally breathing in things like food or liquid; and suicidal ideation in people using these medications.”The appearance of a drug on this list does not mean that FDA has concluded that the drug has the listed risk,” the FAERS website notes. “It means that FDA has identified a potential safety issue, but it does not mean that FDA has identified a causal relationship between the drug and the listed risk.”People who use these medications and have questions or concerns about side effects should speak with their health care provider, the FDA says.”The FDA monitors the safety of drugs throughout their life cycle, including post-approval. In addition, the FDA maintains a system of postmarketing surveillance and risk assessment programs to identify and evaluate adverse events that did not appear during the drug development process,” the agency told CNN on Wednesday. “If newly identified safety signals are identified, the FDA will determine what, if any, actions are appropriate after a thorough review of available data.”These actions may include requiring labeling changes or development of a Risk Evaluation and Mitigation Strategy, a program that helps ensure a medication’s benefits outweigh its risks.Some research has linked GLP-1 agonists to serious digestive problems such as stomach paralysis, pancreatitis and bowel obstructions, although the risks of these events appear to be rare. Many of these side effects are mentioned in the drugs’ prescribing information or on their labels.The American Society of Anesthesiologists recommended in June that people who use GLP-1 agonists stop taking them for a week before surgical procedures because of the potential for gastrointestinal problems like nausea, vomiting and delayed gastric emptying that may “increase the risk of regurgitation and pulmonary aspiration of gastric contents during general anesthesia and deep sedation.” Vomiting under anesthesia sometimes causes food and stomach acid to get into the lungs, which can cause pneumonia and other problems after surgery.For months, European regulators have also been investigating the risk of suicidal thoughts in people taking these medications, although it’s not clear whether the medicines caused the events or whether they may be linked to other underlying conditions.Novo Nordisk, which makes a number of the GLP-1 agonists, said in a statement Wednesday that patient safety is its top priority. The company said it works closely with the FDA to monitor safety and is aware of the reports of side effects.”Novo Nordisk stands behind the safety and efficacy of all of our GLP-1RA medicines when they are used as indicated and when they are taken under the care of a licensed healthcare professional.”

The U.S. Food and Drug Administration is evaluating reports of side effects such as hair loss and suicidal thoughts in people taking medications like Ozempic, Mounjaro and Wegovy.

These drugs, known as GLP-1 receptor agonists, are approved to treat diabetes or weight loss. They include semaglutide, branded as Ozempic, Rybelsus and Wegovy; liragutide, branded as Saxenda and Victoza; and tirzepatide, branded as Mounjaro and Zepbound. They mimic GLP-1, a hormone made naturally in the body whose roles include slowing the passage of food through the stomach.

The FDA is “evaluating the need for regulatory action” after its FDA Adverse Event Reporting System or FAERS received reports of alopecia, or hair loss; aspiration, or accidentally breathing in things like food or liquid; and suicidal ideation in people using these medications.

“The appearance of a drug on this list does not mean that FDA has concluded that the drug has the listed risk,” the FAERS website notes. “It means that FDA has identified a potential safety issue, but it does not mean that FDA has identified a causal relationship between the drug and the listed risk.”

People who use these medications and have questions or concerns about side effects should speak with their health care provider, the FDA says.

“The FDA monitors the safety of drugs throughout their life cycle, including post-approval. In addition, the FDA maintains a system of postmarketing surveillance and risk assessment programs to identify and evaluate adverse events that did not appear during the drug development process,” the agency told CNN on Wednesday. “If newly identified safety signals are identified, the FDA will determine what, if any, actions are appropriate after a thorough review of available data.”

These actions may include requiring labeling changes or development of a Risk Evaluation and Mitigation Strategy, a program that helps ensure a medication’s benefits outweigh its risks.

Some research has linked GLP-1 agonists to serious digestive problems such as stomach paralysis, pancreatitis and bowel obstructions, although the risks of these events appear to be rare. Many of these side effects are mentioned in the drugs’ prescribing information or on their labels.

The American Society of Anesthesiologists recommended in June that people who use GLP-1 agonists stop taking them for a week before surgical procedures because of the potential for gastrointestinal problems like nausea, vomiting and delayed gastric emptying that may “increase the risk of regurgitation and pulmonary aspiration of gastric contents during general anesthesia and deep sedation.” Vomiting under anesthesia sometimes causes food and stomach acid to get into the lungs, which can cause pneumonia and other problems after surgery.

For months, European regulators have also been investigating the risk of suicidal thoughts in people taking these medications, although it’s not clear whether the medicines caused the events or whether they may be linked to other underlying conditions.

Novo Nordisk, which makes a number of the GLP-1 agonists, said in a statement Wednesday that patient safety is its top priority. The company said it works closely with the FDA to monitor safety and is aware of the reports of side effects.

“Novo Nordisk stands behind the safety and efficacy of all of our GLP-1RA medicines when they are used as indicated and when they are taken under the care of a licensed healthcare professional.”



Source link

Latest articles

Wendell Pierce is your new Perry White in James Gunn’s Superman

Say what you will about James Gunn, but the man can cast a...

Beyonce rocks a mullet, red hair, bangs and more for CR Fashion Book

Beyoncé may be one of one, but for her latest magazine cover, she's...

Walgreens, CVS to begin selling abortion pill mifepristone in some states

Walgreens and CVS said Friday that they are preparing to dispense the abortion...

Format and Teams Finalized for 2024 Lamar Hunt U.S. Open Cup

CHICAGO (March 1, 2024) – U.S. Soccer has finalized the format for the...

More like this

Wendell Pierce is your new Perry White in James Gunn’s Superman

Say what you will about James Gunn, but the man can cast a...

Beyonce rocks a mullet, red hair, bangs and more for CR Fashion Book

Beyoncé may be one of one, but for her latest magazine cover, she's...

Walgreens, CVS to begin selling abortion pill mifepristone in some states

Walgreens and CVS said Friday that they are preparing to dispense the abortion...